Drug Discovery@nature.com 5 July 2013

TABLE OF CONTENTS 5 July 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement SciBX is pleased to present: SciBX Summit on Innovation in Drug Discovery and Development 2013 October 29-30, 2013 The Colonnade Hotel, Boston, MA, USA  Click here for more information or to register for this conference today!   News Top New checkpoint inhibitors ride the immunotherapy tsunami doi:10.1038/nrd4066 Immunotherapies that target the PD1–PDL1 axis continue to generate solid clinical data, and fresh combination trial results offer tantalizing hints of greater effectiveness to come. Full Text First-in-class insomnia drug on the brink of approval nod doi:10.1038/nrd4067 Merck's dual orexin receptor antagonist suvorexant is approaching the regulatory finish line, 15 years after orexins were discovered. Full Text Market watch: Upcoming market catalysts in Q3 2013 doi:10.1038/nrd4056 Notable market catalysts include Phase III data for Regeneron's PCSK9 inhibitor and a decision from the US FDA on the approval of Boehringer Ingelheim's kinase inhibitor afatinib for non-small-cell lung cancer. Full Text Deal watch: AbbVie invests in pioneering celiac disease therapy doi:10.1038/nrd4063 AbbVie and Alvine Pharmaceuticals have teamed up to develop ALV003, a novel oral treatment for patients with celiac disease that is in Phase II trials. Full Text Analysis Top New hope for dry AMD? doi:10.1038/nrd4038 There are no specific drugs on the market for dry age-related macular degeneration (AMD), but a pipeline of promising therapies are in development. Full Text Agonizing switch in prostate cancer doi:10.1038/scibx.2013.615 Aragon researchers have uncovered how a specific androgen receptor mutation turns second-generation antagonists for prostate cancer into agonists. The results could allow the company, which is being acquired by Johnson & Johnson, to develop third-generation molecules that overcome the resistance mechanism. Full Text Research Highlights Top Tumour immunology: Cracking the combination doi:10.1038/nri3481 Combined immunotherapies target macrophages and regulatory T cells to enhance antitumour responses. Full Text Metabolic disorders: Betatrophin boosts β-cells doi:10.1038/nrd4058 A novel liver-secreted hormone named betatrophin promotes β-cell proliferation and improves glucose tolerance in mice. Full Text Cancer: IL-22: linking inflammation and cancer doi:10.1038/nrd4065 IL-22 is a key player in the transition from intestinal inflammation to cancer. Full Text Research & Reviews Top Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease doi:10.1038/nrd4024 The therapeutic application of neurotrophins is limited by their poor pharmacological properties and undesirable pleiotropic actions. Targeting individual neurotrophin receptors using small-molecule ligands may overcome these limitations. Full Text New anti-inflammatory targets for chronic obstructive pulmonary disease doi:10.1038/nrd4025 This article highlights new therapeutic targets for COPD that have been discovered through a better understanding of the underlying inflammation, and discusses the development of anti-inflammatory drugs for this disorder. Full Text Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host doi:10.1038/nrc3486 The authors propose a model that suggests a new approach to cancer diagnosis and therapy that focuses on epigenetic dysregulation, and discuss its potential for risk detection and chemoprevention. Full Text In vivo cardiac reprogramming contributes to zebrafish heart regeneration doi:10.1038/nature12322 A cardiac injury study in zebrafish reveals the plasticity of heart cell lineages as shown by a Notch-dependent transdifferentiation of atrial to ventricular cardiomyocytes, regenerating a cell type that is damaged in human heart failure. Full Text Drug Discovery JOBS of the week Postdoc in Computational Drug Design University of Copenhagen - Faculty of Medical and Health Sciences Postdoctoral Scholar Position in Nanoparticles and Drug Delivery, University of California, Los Angeles UCLA Research Laboratory Head (M / F) Cancer Drug Discovery Boehringer Ingelheim RCV GmbH & Co KG Microbiologist for Antibiotic Drug Development AntibioTx ApS Postdoctoral Fellow – Drug Discovery / GU Oncology Moffitt Cancer Center & Research Institute More Science jobs from Drug Discovery EVENT Venomics: Drug Discovery from Nature's Deadliest 04.11.13 New York, USA More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.